Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies.

开始日期2024-12-01

申办/合作机构

Gilead Sciences, Inc.

[+1]

NCT06133517

/ Not yet recruiting临床2期IIT

An Open Label, Single-arm, Phase 2 Study of Perioperative Sacituzumab Govitecan in Combination With Zimberelimab and Domvanalimab for Patients With Muscle Invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy

The main objective of this trial is to evaluate the efficacy of the combo Sacituzumab govitecan (SG) + Zimberelimab (AB 122) (ZIM) + Domvanalimab (AB 154) (DOM), measured as pathologic complete response (pCR) rates, in the perioperative setting in patients with Muscle Invasive Bladder Cancer (MIBC) who are either unfit for platinum-based chemotherapy or unwilling to receive that therapy.

开始日期2024-10-01

申办/合作机构

Apices Soluciones SL

NCT06250036

/ Not yet recruiting临床2期IIT

A Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunotherapy in Resectable Mismatch Repair Deficient Gastric and Gastro-oesophageal Junctional AdenoCarcinoma

A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)

开始日期2024-04-01

申办/合作机构

Royal Marsden NHS Foundation Trust

[+1]

100 项与 Domvanalimab 相关的临床结果

登录后查看更多信息

100 项与 Domvanalimab 相关的转化医学

登录后查看更多信息

100 项与 Domvanalimab 相关的专利（医药）

登录后查看更多信息

项与 Domvanalimab 相关的文献（医药）

2024-05-01·Clinical lung cancer

STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non–Small Cell Lung Cancer With No Actionable Gene Alterations

Article

作者: Rodriguez-Abreu, Delvys ; Johnson, Melissa ; Todd, Trever ; Gray, Jhanelle E ; Chen, Xueying ; Yu, Xinwei ; Mohammad, Saad ; Bosch-Barrera, Joaquim ; Kim, Jongseok ; Ahn, Myung-Ju ; Reck, Martin

INTRODUCTION:

Dual inhibition with a T-cell immunoreceptor with immunoglobulin and ITIM domains plus programmed death (ligand)-1 (PD[L]-1) inhibitors, with or without chemotherapy, is an emerging therapeutic strategy in metastatic non-small cell lung cancer (mNSCLC). The STAR-121 (NCT05502237) phase III, global, randomized, open-label study will investigate first-line domvanalimab (anti-TIGIT) and zimberelimab (anti-PD-1) plus chemotherapy versus pembrolizumab plus chemotherapy in mNSCLC with no actionable gene alterations.

PARTICIPANTS AND METHODS:

Approximately 720 participants (≥18 years old) with untreated mNSCLC and no EGFR and ALK mutations will be randomized into 3 groups (A, B, or C) in a 4:4:1 ratio and stratified by baseline PD-L1 expression (tumor cells <50% vs. ≥50%), histology (squamous vs. nonsquamous), and geographic region (East Asia vs. non-East Asia). Group A will receive domvanalimab 1200 mg plus zimberelimab 360 mg plus platinum-doublet chemotherapy (PT), group B will receive pembrolizumab 200 mg plus PT, and group C will receive zimberelimab 360 mg plus PT, every 3 weeks. Treatment will be administered until disease progression or intolerable toxicity. Dual primary endpoints are progression-free survival (by blinded independent central review [BICR]) and overall survival for group A versus B. Key secondary endpoints comprise overall response rate (by BICR), safety, and quality of life. Exploratory endpoints include efficacy and safety between groups A and C, pharmacokinetics, patient-reported outcomes, and biomarkers.

CONCLUSION:

Enrollment in the STAR-121 study commenced on October 12, 2022, and is currently ongoing with completion planned by September 2024. The study completion is expected by December 2027.

2015-01-01·The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics4区 · 医学

Eggs and Abortion: "Women-Protective" Language Used by Opponents in Legislative Debates over Reproductive Health.

4区 · 医学

Article

作者: Weitz, Tracy ; Jesudason, Sujatha

In this paper we undertake an examination of the presence of similar "women-protective" discourses in policy debates occurring over two bills on reproductive-related topics considered during the 2013 California legislature session. The first bill (AB154), now signed into law, allows nurse practitioners, certified nurse midwives, and physician assistants to perform first-trimester aspiration abortions. The second bill (AB926), had it passed, would remove the prohibition on paying women for providing eggs to be used for research purposes. Using frame analysis we find evidence of similar protective arguments by opponents of both bills, although these advocates do not share ideological positions on abortion rights or women's autonomy. In the case of AB154, anti-abortion advocates use language and frames that call for protecting the health of women against the imputed interests of the "abortion industry." In the case of AB926, feminists and pro-choice advocates evoke similar frameworks for the protection of women against the interests of the "medical research industry." Both sides argue for the "protection of women," from opposing positions on the rights and autonomy of women in relationship to reproductive freedom.

155

项与 Domvanalimab 相关的新闻（医药）

2024-12-23

·奇点网

扶我起来，TIGIT还没凉呢

*仅供医学专业人士阅读参考如果要评选一个免疫治疗领域的“最惨靶点”，那奇点糕肯定会把票投给TIGIT：就在前两天，曾备受期待的TIGIT抑制剂Tiragolumab又挨了一闷棍，一线联合PD-L1抑制剂治疗肺癌的关键临床研究终究没达到阳性结果，恐怕在肺癌领域彻底翻身无望了。但同样是联合PD-L1抑制剂，TIGIT抑制剂治疗胃癌和食管癌的临床研究，近一年来可是喜报频传[1]。所以说，现在还真不能对TIGIT抑制剂的命运下定论，东方不亮西方亮也不是什么稀罕事，还是要更深入地了解TIGIT抑制剂的起效机制，帮它们找到适合的赛道和使用场景才行。近日，开发Tiragolumab的基因泰克（Genentech）公司团队就在Nature Cancer期刊发表最新研究成果[2]，揭示了TIGIT抑制剂与PD-L1抑制剂联合见效的最新作用机制证据。研究发现，同时抑制TIGIT与PD-L1可使肿瘤引流淋巴结（TDLNs）中的肿瘤反应性CD8+T细胞，在CD226的驱动下发生数量扩增并进入血液，随后肿瘤反应性CD8+T细胞浸润到肿瘤前，抑制TIGIT与PD-L1也会通过营造共刺激条件，使它们向效应表型而非耗竭表型分化，让进入肿瘤部位的CD8+T细胞更有利于发挥抗癌作用。论文首页截图基因泰克团队本次研究的切入点，是评估TIGIT抑制剂与PD-L1抑制剂是否会在T细胞激活的不同阶段或不同部位发挥作用，为此实验首先在小鼠模型上展开：联合使用TIGIT抑制剂与PD-L1抑制剂的抑癌效果明显优于二者分别单用，但联合治疗并未显著改变肿瘤或TDLNs的CD8+T细胞总数，而TDLNs当中的肿瘤反应性CD8+T细胞占比明显上升。与此同时，小鼠外周血内的肿瘤反应性CD8+T细胞也明显增多，但在联合治疗开始后早期使用免疫抑制剂盐酸芬戈莫德（FTY720），特异性阻断T细胞从TDLNs经血液循环的迁移，就会使TIGIT抑制剂与PD-L1抑制剂联合治疗的效果消失，意味着联合治疗必须依赖于肿瘤反应性CD8+T细胞经血液循环浸润到肿瘤部位这条路。TIGIT抑制剂与PD-L1抑制剂起效，依赖于肿瘤反应性CD8+T细胞经血液循环浸润到肿瘤研究者们根据表面标志物表达情况对肿瘤反应性CD8+T细胞进行了细分，发现在联合治疗后扩增的亚群以表达CD226为特征，且属于效应表型或耗竭表型，但联合治疗不会影响CD226表达阴性的肿瘤反应性CD8+T细胞；在肿瘤部位，受联合治疗影响的肿瘤反应性CD8+T细胞则会表达转录因子TCF1，意味着它们具有干细胞样特征，而换到TDLNs内，肿瘤反应性CD8+T细胞经联合治疗后的转录因子TOX表达减少，提示更不易走向耗竭。借助抗CD226单抗，研究者们又证实在TDLNs中，TIGIT抑制剂+PD-L1抑制剂对肿瘤反应性CD8+T细胞的调控确实依赖于CD226存在，TDLNs也是肿瘤反应性CD8+T细胞发生克隆扩增的主要部位；而且，肿瘤中浸润的CD8+T细胞也都经历过在TDLNs扩增这一步，后续浸润到肿瘤还会继续扩增，把肿瘤内“土生土长”的CD8+T细胞基本都挤走。对CD8+T细胞轨迹变化的分析则显示，TDLNs内具有干细胞样特征的一部分T细胞（特征为高表达Slamf6和Tcf7，类似记忆性干细胞样T细胞），是细胞毒性CD8+T细胞的主要来源；TIGIT抑制剂+PD-L1抑制剂的联合治疗，则会使肿瘤反应性CD8+T细胞更易发生迁移，且它们抵达肿瘤部位后更易分化为细胞毒性表型，杀伤癌细胞的能力更强，同时不易向肿瘤内原有CD8+T细胞的近似耗竭表型分化（PD-L1抑制剂+盐酸芬戈莫德处理可诱导）。TIGIT抑制剂+PD-L1抑制剂联合治疗对肿瘤反应性CD8+T细胞的整体影响总而言之，TIGIT抑制剂+PD-L1抑制剂联合治疗能够定向招募肿瘤反应性CD8+T细胞，并提升它们的整体质量，而不仅仅只有数量增多，这才是成功调动抗肿瘤免疫应答的关键。但从治疗消化道肿瘤的情况来看，好像TIGIT抑制剂+PD-L1抑制剂的双人成行还不够给力，总得加点化疗之类的元素才能真正成为“爆款”，看看未来科学家们还能挖出什么机制吧。参考文献：[1]Rha S Y, Oh D Y, Pelster M, et al. 130MO EDGE-Gastric Arm A1: Phase II study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer[J]. Annals of Oncology, 2024, 35(Supplement 4): S1455.[2]Nutsch K, Banta K L, Wu T D, et al. TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation[J]. Nature Cancer, 2024.本文作者丨谭硕

免疫疗法

2024-12-17

·Endpoints

Merck winds down TIGIT, LAG-3 programs meant to temper Keytruda erosion

After multiple clinical failures, it’s finally the end of the road for Merck’s TIGIT program. The company is dropping development of its anti-TIGIT candidate vibostolimab after two more Phase 3 studies of a fixed-dose combination with Keytruda ended in disappointment. Merck is also discontinuing a separate LAG-3 targeting antibody asset called favezelimab, which it was also testing alongside Keytruda, according to a company release Tuesday. The pipeline cuts mean Merck won’t be able to stave off generic competition for its blockbuster PD-1 medicine by launching fixed-dose combinations with other targeted therapies, Leerink analysts wrote Tuesday. They added that the drugmaker will instead have to focus on converting patients to a subcutaneous formulation of Keytruda, which could launch as soon as next year. The decision to nix vibostolimab was made after two trials of the drug plus Keytruda in certain patients with non-small cell lung cancer — KeyVibe-003 and KeyVibe-007 — met prespecified futility criteria for the overall survival primary endpoint. These flops add to a spate of late-stage disappointments earlier this year in small cell lung cancer and skin cancer . The company is also axing the KeyVibe-006 test of vibostolimab plus Keytruda and chemoradiotherapy in stage 3 NSCLC, which is still enrolling, according to clinicaltrials.gov. Merck did not offer much explanation of what drove the most recent failures, but the Leerink analysts said TIGIT/PD-1 combinations tend to have high levels of toxicity that can lead to patients discontinuing treatment, making it difficult to establish a long-term survival benefit. Merck is not the only drugmaker that has struggled with developing TIGITs. Last month, Roche’s candidate tiragolumab plus its PD-L1 drug Tecentriq missed the OS primary endpoint in a registrational NSCLC test. But there’s still potential for TIGIT drugs that are Fc-incompetent because they could have better safety, the Leerink analysts said. These include Gilead and Arcus’ domvanalimab and Compugen’s COM902. Elsewhere, Merck stopped enrollment in the Phase 3 KEYFORM-008 trial of a fixed-dose combination of favezelimab and Keytruda in certain patients with relapsed or refractory classical Hodgkin lymphoma as it ended the broader KEYFORM development program. The company said the decision was not driven by safety concerns. In September, the favezelimab regimen failed a separate study in metastatic colorectal cancer.

临床3期临床失败临床终止

2024-12-12

·UmabsDB

PD-1+TIGIT：吉利德启动一线头颈鳞癌联合疗法临床

Umabs DB作为目前全球最全面的抗体药物专业数据库，收录全球近10000个从临床前到商业化阶段抗体药物，涉及靶点1600+，涉及疾病种类2400+，研发机构2900+，覆盖药物蛋白序列、专利和临床等多种专业信息。Umabs DB药物数据库已正式开放上线，可访问www.umabs.com注册享受7天免费试用。近期，根据UmabsDB数据库的记录，吉利德在clinical trials网站上，登记了一项TIGIT抗体domvanalimab (DOM) ，联合PD-1抗体zimberelimab (ZIM) 和化疗，在一线头颈鳞癌癌患者中启动一项2期临床试验NCT06727565，该临床将于2025年2月启动，计划入组人数为100例。 TIGIT抗体domvanalimab (DOM) +PD-1抗体zimberelimab (ZIM) 的组合疗法，是吉利德和Arcus合作开发的，DOM为Fc沉默的TIGIT抗体，PD-1抗体zimberelimab (ZIM) 引进来自于中国誉衡生物，此前该组合疗法已经在一线胃癌和一线非小细胞肺癌中先期启动三期临床。今年公布的一线胃癌和非小细胞肺癌早期临床数据显示，联合治疗数据较为积极，特别是在刚刚结束的SITC会议上，在一线非小细胞肺癌中，组合疗法相对于PD-1单药，PFS和OS HR分别达到了0.69和0.64，三期临床值得期待。回到TIGIT抗体疗法，罗氏的Tiragolumab一败再败（罗氏TIGIT抗体一线肺癌再次失败）,但是值得注意的是，Tiragolumab是一种具有完整Fc功能的抗体，吉利德和Arcus的domvanalimab是全球唯一在三期非小细胞肺癌临床中使用Fc沉默的抗体，其避免了外源Treg细胞的清除。但是在Treg清除方面，GSK和iTeos合作开发的TIGIT抗体Belrestotug基于特殊的表位，对于Treg清除能力明显。在一线非小细胞肺癌的二期临床中，与PD-1抗体dostarlimab单药治疗的28.1%响应率相比，三个剂量组情况下，belrestotug/dostarlimab组合在 PD-L1 高的一线非小细胞肺癌患者的客观响应率ORR分别达到了 60%以上，确认情况下的客观响应率ORR似乎并没有呈现剂量依赖性，安全性方面联用组也没有出现明显变化，这也成为TIGIT目前为数不多的希望，目前也已经开展三期临床试验（响应率提高一倍：GSK的TIGIT+PD-1联合疗法在非小细胞肺癌领域取得突破）。再回到一线头颈鳞癌，今年以来进展显著，多个产品启动三期临床试验。Merus在今年ASCO期间，公布的EGFR x LGF5双抗petosemtamab用于一线头颈部鳞状细胞癌数据，单药一线治疗响应率为37%。Bicara的PD-L1/TGF-β双抗ficerafusp alfa (BCA101)，联合帕博利珠单抗的响应率为54%，但单药一线治疗还未出现响应。 ESMO会议期间，康方了公布了的PD-L1表达阳性复发/转移性头颈部鳞状细胞癌二期数据显示，PD-1/VEGF双抗药物AK112联和CD47单抗的响应率到60%，中位PFS达到7.1个月。几周前，Pyxis Oncology宣布了其靶向 Extradomain-B 纤连蛋白 (EDB+FN)的ADC药物 PYX-201在小规模临床中单药条件下取得了50%的ORR，未来值得期待，同时基于良好的安全性，未来也有机会和K药进行联合治疗（非细胞抗原：PYXIS公开EDB+FN ADC临床数据，65位患者ORR达到26%）。期待DOM+ZIM组合疗法早日传来临床捷报，更多有关抗体的研发格局、具体信息、专利及临床等动态进展，敬请访问Umabs DB全球数据库（www.umabs.com）查阅。拓展阅读：中位OS提高10.9个月：Immutep启动LAG-3+PD-1一线非小细胞肺癌头对头三期临床试验 Macrogenics启动下一代ADAM9 ADC临床 100% CR：默沙东更新ROR1 ADC二期淋巴瘤临床数据，即将启动三期临床 MSD：收购PD-1/VEGF双抗后的回应 HIV：中裕新药将ADC拓展至抗病毒领域全球首个：默沙东ROR1 ADC启动三期临床试验 HER3终成药：HER2/HER3双抗Zenocutuzumab获FDA批准上市百利天恒两款ADC在美启动临床 3000万美元首付：GSK引进映恩一款临床前ADC药物 “四字编码”时代下的信达全梳理 BioNtech启动PD-L1/VEGF双抗肺癌两项头对头三期临床大涨68%：Janux的PSMA/CD3双抗再次取得突破疗效 316例：诺华启动BAFF-R抗体在狼疮性肾炎的三期临床 250例：默克CEACAM5 ADC开展泛癌种临床试验 AK112 vs PM8002：PD-1/VEGF第三次交锋康方生物两款PD-1双抗均进入2024年医保目录 234例：安领科启动EGFR/c-Met双抗ADC临床科伦博泰：本土首款Trop2 ADC获批上市罗氏TIGIT抗体一线肺癌再次失败 876例：恒瑞启动c-met ADC单药及多种药物联用临床科伦博泰首个双抗ADC启动临床阿斯利康：ADC药物的临床剂量转化策略最惨18A：北海康成市值仅为7520万港元，累计跌幅达到98.55% 2~3分钟完成给药：K药皮下制剂三期临床取得成功 ORR仅为5%：Immatics公布PRAME/CD3 TCR双抗临床数据石药启动EGFR ADC+ATM抑制剂联合治疗临床康方启动CD73/LAG3双抗临床试验宫颈癌：迈威Nectin-4 ADC启动第3项三期临床大涨53%：中国资产再次拯救美股biotech 翰森HS-20124为ROR-1 ADC药物？翰森公开SEZ6 ADC专利翰森公开CDH17 ADC专利复宏汉霖公布两款ADC药物专利 BioNtech: 2024研发日默沙东终于信了：5.88亿美元首付款引进礼新PD-1/VEGF双抗映恩公开PD-L1/B7H3双抗ADC临床前数据 Hexagon：新型ADC毒素提高渗透性：antikor开发高DAR值片段抗体ADC Genmab终止两款CD3双抗开发，重聚焦后期管线第一三共开发皮下HER2 ADC 三抗来袭：Aditum Bio以3500万美元首付款引进维立志博CD3/CD19/BCMA 强生公布膜依赖性MSLN/CD3双抗金赛公开自主开发TOPOi ADC平台礼来公布PTK7 ADC药物临床前数据双payload ADC逐步工业化，多款药物即将进入临床恒瑞SHR-A2009：国内首个HER3 ADC进入三期 ADC：抗原高表达的必要性？关于Umabs DB Umabs DB是目前全球最全面的抗体药物专业数据库，收录全球近10000个从临床前到商业化阶段抗体药物，涉及靶点1600+，涉及疾病种类2400+，研发机构2900+，覆盖药物蛋白序列、专利和临床等多种专业信息。Umabs DB药物数据库已正式开放上线，可访问www.umabs.com注册享受7天免费试用，更多信息可联系info@umabs.com

临床3期ASCO会议临床2期临床结果临床失败

100 项与 Domvanalimab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
食管腺癌	临床3期	美国	吉利德（上海）医药科技有限公司	2022-11-21
食管腺癌	临床3期	日本	吉利德（上海）医药科技有限公司	2022-11-21
食管腺癌	临床3期	阿根廷	吉利德（上海）医药科技有限公司	2022-11-21
食管腺癌	临床3期	澳大利亚	吉利德（上海）医药科技有限公司	2022-11-21
食管腺癌	临床3期	比利时	吉利德（上海）医药科技有限公司	2022-11-21
食管腺癌	临床3期	巴西	吉利德（上海）医药科技有限公司	2022-11-21
食管腺癌	临床3期	加拿大	吉利德（上海）医药科技有限公司	2022-11-21
食管腺癌	临床3期	智利	吉利德（上海）医药科技有限公司	2022-11-21
食管腺癌	临床3期	法国	吉利德（上海）医药科技有限公司	2022-11-21
食管腺癌	临床3期	格鲁吉亚	吉利德（上海）医药科技有限公司	2022-11-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04736173 (ARC-10, BusinessWire) 人工标引	临床1期	PD-L1阳性非小细胞肺癌 PD-L1 High Expression	98	Domvanalimab plus Zimberelimab	獵遞簾製艱構夢艱網淵(衊餘糧鬱築願艱蓋鏇顧) = 選膚願獵鬱鬱蓋遞鏇廠顧壓鏇鑰簾窪選遞遞膚 (膚簾衊鹹鹽築醖廠醖積, 13.7 ~ NE) 更多	积极	2024-11-05
				Zimberelimab	獵遞簾製艱構夢艱網淵(衊餘糧鬱築願艱蓋鏇顧) = 衊廠夢構願築餘衊鬱襯顧壓鏇鑰簾窪選遞遞膚 (膚簾衊鹹鹽築醖廠醖積, 7.8 ~ NE) 更多
NCT05329766 (EDGE-Gastric, BusinessWire) 人工标引	临床2期	胃肠道肿瘤一线 PD-L1	41	domvanalimab+Zimberelimab+ Chemotherapy	鑰顧觸餘齋鬱壓淵簾艱(餘蓋餘廠膚範鏇壓築鑰) = 遞鏇鏇夢醖選鹹簾艱遞膚糧築齋願餘艱衊製廠 (簾簾醖鹹餘築遞憲蓋膚, 9.8 ~ 13.8) 更多	积极	2024-06-01
				domvanalimab+Zimberelimab+ Chemotherapy (PD-L1-high)	鑰顧觸餘齋鬱壓淵簾艱(餘蓋餘廠膚範鏇壓築鑰) = 淵壓夢膚衊願築膚簾網膚糧築齋願餘艱衊製廠 (簾簾醖鹹餘築遞憲蓋膚, 11.3 ~ NE) 更多
NCT05329766 (EDGE-Gastric, Corporate Publications) 人工标引	临床2期	食管腺癌 \| 局部晚期不可切除的胃腺癌 \| 转移性胃食管结合部腺癌一线	41	Domvanalimab+zimberelimab+chemotherapy	遞餘艱鹹窪繭廠遞簾夢(鏇艱選齋鬱襯夢網鏇遞) = 窪網鹽製獵鹽蓋糧製鬱夢醖簾鹽糧簾鑰壓壓願 (廠膚膚鹽鹽衊製構繭衊, 42 ~ 74) 更多	积极	2023-11-06
				Domvanalimab+zimberelimab+chemotherapy (PD-L1-high* (TAP ≥5%))	遞餘艱鹹窪繭廠遞簾夢(鏇艱選齋鬱襯夢網鏇遞) = 選觸願獵觸構遞構衊襯夢醖簾鹽糧簾鑰壓壓願 (廠膚膚鹽鹽衊製構繭衊, 52 ~ 96) 更多
NCT04262856 (ARC-7, Corporate Publications) 人工标引	临床2期	非小细胞肺癌一线	150	zimberelimab	觸遞鬱廠鏇積壓衊衊糧(膚範艱膚壓鹹糧鏇壓鹽) = 構淵廠齋網繭願觸獵襯遞鬱蓋廠鑰齋觸艱夢鹹 (齋窪淵鏇鑰艱蓋獵遞膚, 17.9 ~ 44.6) 更多	积极	2023-06-03
				domvanalimab + zimberelimab	觸遞鬱廠鏇積壓衊衊糧(膚範艱膚壓鹹糧鏇壓鹽) = 積獵壓壓鬱範鏇範艱鑰遞鬱蓋廠鑰齋觸艱夢鹹 (齋窪淵鏇鑰艱蓋獵遞膚, 26.4 ~ 54.8) 更多
NCT04262856 (ARC-7, ASCO2022) 人工标引	临床2期	转移性非小细胞肺癌一线 PD-L1 High Expression	149	zimberelimab	鏇餘獵選鑰憲網淵壓構(襯獵夢淵網壓壓壓積獵) = 選製鹽鏇膚選艱艱觸糧夢網簾鹽製鹽蓋襯願範 (顧鏇觸齋繭衊積憲鑰獵, 15.0 ~ 42.8) 更多	积极	2022-12-20
				domvanalimab+zimberelimab	鏇餘獵選鑰憲網淵壓構(襯獵夢淵網壓壓壓積獵) = 窪選艱獵鏇願窪鏇構鑰夢網簾鹽製鹽蓋襯願範 (顧鏇觸齋繭衊積憲鑰獵, 26.3 ~ 56.8) 更多